Whole-Genome Landscape of Pancreatic Neuroendocrine Tumours
Aldo Scarpa,David K. Chang,Katia Nones,Vincenzo Corbo,Ann-Marie Patch,Peter Bailey,Rita T. Lawlor,Amber L. Johns,David K. Miller,Andrea Mafficini,Borislav Rusev,Maria Scardoni,Davide Antonello,Stefano Barbi,Katarzyna O. Sikora,Sara Cingarlini,Caterina Vicentini,Skye McKay,Michael C. J. Quinn,Timothy J. C. Bruxner,Angelika N. Christ,Ivon Harliwong,Senel Idrisoglu,Suzanne McLean,Craig Nourse,Ehsan Nourbakhsh,Peter J. Wilson,Matthew J. Anderson,J. Lynn Fink,Felicity Newell,Nick Waddell,Oliver Holmes,Stephen H. Kazakoff,Conrad Leonard,Scott Wood,Qinying Xu,Shivashankar Hiriyur Nagaraj,Eliana Amato,Irene Dalai,Samantha Bersani,Ivana Cataldo,Angelo P. Dei Tos,Paola Capelli,Maria Vittoria Davì,Luca Landoni,Anna Malpaga,Marco Miotto,Vicki L. J. Whitehall,Barbara A. Leggett,Janelle L. Harris,Jonathan Harris,Marc D. Jones,Jeremy Humphris,Lorraine A. Chantrill,Venessa Chin,Adnan M. Nagrial,Marina Pajic,Christopher J. Scarlett,Andreia Pinho,Ilse Rooman,Christopher Toon,Jianmin Wu,Mark Pinese,Mark Cowley,Andrew Barbour,Amanda Mawson,Emily S. Humphrey,Emily K. Colvin,Angela Chou,Jessica A. Lovell,Nigel B. Jamieson,Fraser Duthie,Marie-Claude Gingras,William E. Fisher,Rebecca A. Dagg,Loretta M. S. Lau,Michael Lee,Hilda A. Pickett,Roger R. Reddel,Jaswinder S. Samra,James G. Kench,Neil D. Merrett,Krishna Epari,Nam Q. Nguyen,Nikolajs Zeps,Massimo Falconi,Michele Simbolo,Giovanni Butturini,George Van Buren,Stefano Partelli,Matteo Fassan,Kum,Anthony J. Gill,David A. Wheeler,Richard A. Gibbs,Elizabeth A. Musgrove,Claudio Bassi,Giampaolo Tortora,Paolo Pederzoli,John V. Pearson,Nicola Waddell,Andrew V. Biankin,Sean M. Grimmond
DOI: https://doi.org/10.1038/nature21063
IF: 64.8
2017-01-01
Nature
Abstract:Neuroendocrine tumours (NETs) may arise throughout the body and are a highly heterogeneous, relatively rare class of neoplasms difficult to study also for the lack of disease models. Despite this, knowledge on their molecular alterations has expanded in the latest years, also building from genetic syndromes causing their onset. Pancreatic NETs (PanNETs) have been among the most studied, and research so far has outlined a series of recurring features, as inactivation of MEN1, VHL, TSC1/2 genes and hyperactivation of the PI3K/mTOR pathway. Next-generation sequencing has added new information by showing the key role of alternative lengthening of telomeres, driven in a fraction of PanNETs by inactivation of ATRX/DAXX. Despite this accumulation of knowledge, single studies often relied on few cases or were limited to the DNA, RNA, protein or epigenetic level with lack of integrative analysis. The International Cancer Genome Consortium aimed at removing these barriers through a strict process of data and samples collection, to produce whole-genome integrated analyses for many tumour types. The results of this effort on PanNETs have been recently published and, while confirming previous observations provide a first snapshot of how heterogeneous is the combination of genetic alterations that drive this tumour type, yet converging into four pathways whose alteration has been enriched by newly discovered mechanisms. While calling for further integration of genetic and epigenetic analyses, these data allow to reconcile previous findings in a defined frame and may provide clinical research with markers for patients stratification and to guide targeted therapy decisions.